J. Luccarini

发表

Pharmacological characterization of the bradykinin B2 receptor: inter‐species variability and dissociation between binding and functional responses

D. Pruneau, J. Paquet, J. Luccarini, 1999, British journal of pharmacology.

The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis

I. Leclercq, I. Konstantinova, J. Junien, 2017, Hepatology communications.

CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas

G. Almouzni, J. Waterfall, L. Colombeau, 2022, Nature Communications.

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension

Y. Allanore, J. Avouac, I. Konstantinova, 2017, Annals of the rheumatic diseases.

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

J. Binet, J. Junien, Stéphanie Ferry, 2018, Journal of medicinal chemistry.

LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor

D. Pruneau, J. Paquet, J. Luccarini, 1998, British journal of pharmacology.

Synthesis and in Vivo pharmacological profile of dimeric HOE 140 bradykinin antagonists

Jean Martínez, M. Amblard, D. Pruneau, 2002 .

Synthesis and pharmacological evaluation of dimer derivatives of the bradykinin receptor antagonist HOE-140.

M. Amblard, D. Pruneau, J. Paquet, 2009, The journal of peptide research : official journal of the American Peptide Society.

Pharmacological evidence for a single bradykinin B2 receptor in the guinea‐pig

D. Pruneau, J. Paquet, J. Luccarini, 1995, British journal of pharmacology.

Characterisation of bradykinin receptors from juvenile pig coronary artery.

D. Pruneau, J. Paquet, J. Luccarini, 1996, European journal of pharmacology.

Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.

D. Pruneau, J. Paquet, J. Luccarini, 1999, Immunopharmacology.

In vitro and in vivo effects of the new nonpeptide bradykinin B2 receptor antagonist, LF 16‐0335C, on guinea‐pig and rat kinin receptors

D. Pruneau, J. Paquet, J. Luccarini, 1999, Fundamental & clinical pharmacology.

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis

Y. Allanore, J. Avouac, T. Guilbert, 2015, Annals of the rheumatic diseases.

The kinin B1 receptor antagonist des‐Arg9‐[Leu8]bradykinin: an antagonist of the angiotensin AT1 receptor which also binds to the AT2 receptor

J. Bonnafous, D. Pruneau, J. Luccarini, 1995, British journal of pharmacology.

Induction of kinin B1 receptor‐dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery

D. Pruneau, J. Luccarini, C. Robert, 1994, British journal of pharmacology.

Induction of kinin B 1 receptor-dependent vasoconstriction following balloon catheter injury to the rabbit carotid artery '

D. Pruneau, J. Luccarini, C. Robert, 2022 .

From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.

D. Pruneau, J. Paquet, J. Luccarini, 2012, Journal of medicinal chemistry.

Antinociceptive Pharmacology of N-[[4-(4,5-Dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, Fumarate (LF22-0542), a Novel Nonpeptidic Bradykinin B1 Receptor Antagonist

T. Vanderah, J. Junien, F. Porreca, 2006, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide‐treated rats

D. Pruneau, J. Paquet, J. Luccarini, 1999, British journal of pharmacology.

Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.

M. Amblard, D. Pruneau, J. Paquet, 1999, Journal of medicinal chemistry.

Synthesis and biological evaluation of bradykinin B1/B2 and selective B1 receptor antagonists

Jean Martínez, M. Amblard, D. Pruneau, 2000 .

A rational approach to the design and synthesis of a new bradykinin B(1) receptor antagonist.

M. Amblard, A. Aumelas, G. Subra, 2000, Journal of medicinal chemistry.

Synthesis and characterization of bradykinin B(2) receptor agonists containing constrained dipeptide mimics.

M. Amblard, M. Calmès, D. Pruneau, 1999, Journal of medicinal chemistry.

Cloning and characterization of guinea pig interleukin-8 receptor.

J. Catusse, D. Pruneau, J. Paquet, 2003, Biochemical pharmacology.

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

E. Entchev, J. Junien, A. Bouchot, 2020, PloS one.

Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.

M. Amblard, D. Pruneau, J. Paquet, 2000, Journal of medicinal chemistry.

Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs

D. Pruneau, J. Paquet, J. Luccarini, 1996, British journal of pharmacology.

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.

S. Gauld, K. Cusack, M. Kort, 2019, Bioorganic & medicinal chemistry letters.

Inhibition of Interleukin-23–Mediated Inflammation with a Novel Small Molecule Inverse Agonist of RORγt

S. Gauld, K. Cusack, P. Honore, 2019, The Journal of Pharmacology and Experimental Therapeutics.